CHICAGO--Igenbio, Inc., a genomics and informatics solutions provider, has expanded its service offerings into the human genome analytics market. With its flagship cloud-based Software as a Service (SaaS) analytics platform ERGO, known in the microbial and synthetic biology spaces, Igenbio, Inc. now offers human genome RNA sequence analytics. ERGO provides fully featured coding and non-coding gene expression analytics for RNA-Seq. ERGO's human analytics module is easy to use and surpasses present desktop software offerings for computing differential gene expression, clustering, and variant detection. “ERGO frees scientists from the costly hassle of complex data and software management,” said Vinayak Kapatral Ph.D. President, CEO of Igenbio, Inc.
ERGO's Human analytics module allows the study of normal biological processes, clinical biomarkers, predictive biomarkers, drug target discovery, responses to therapeutic interventions, pathogenic processes, and more.
Chicago-based Igenbio, Inc. specializes in research in genomics, biochemistry, and gene expression. Igenbio, Inc. serves a broad customer base across industry, academic and government institutions. ERGO 2.0 integrates proprietary functional genomic data, metabolic reconstructions, biochemical with genome and gene-centric tools for genome research along with RNA expression analytics.